LEO Pharma

LEO Pharma announces U.S. Food and Drug Administration (FDA) acceptance of Biologics License Application (BLA) for tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis

Share

Submission includes data from pivotal ECZTRA 1, 2 and ECZTRA 3 Phase 3 studies evaluating safety and efficacy of tralokinumab.

BALLERUP, Denmark, and MADISON, NJ, [JULY 9, 2020] – LEO Pharma A/S, a global leader in medical dermatology, today announced that the Biologics License Application (BLA) for tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis (AD) has been accepted for review by the U.S. Food and Drug Administration (FDA). The acceptance of the BLA is the beginning of the formal review procedure for this potential new treatment by the FDA. Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date in the second quarter of 2021.

Tralokinumab is a fully human monoclonal antibody that specifically neutralizes the interleukin-13 (IL-13) cytokine which is a key driver of the underlying inflammation in atopic dermatitis.(1,2) The BLA submission is based on data from the pivotal ECZTRA 1, 2 and ECZTRA 3 Phase 3 studies evaluating the safety and efficacy of tralokinumab.(3,4,5). The safety and efficacy of tralokinumab have not been evaluated by any regulatory authority. 

“There is a significant unmet medical need for people whose moderate-to-severe atopic dermatitis remains uncontrolled,” said Kim Kjøller, M.D., Executive Vice President, Global Research and Development, LEO Pharma. “If approved, tralokinumab could become the first biologic available to specifically neutralize the IL-13 cytokine and, most importantly, offer a more targeted approach for adults living with this debilitating disease. We will continue to work closely with the FDA as they review this application.”

The European Medicines Agency (EMA) recently accepted the marketing authorization application (MAA) for tralokinumab and regulatory review is underway by the Committee for Medicinal Products for Human Use (CHMP).

###

About tralokinumab

Tralokinumab is an investigational, fully human, immunoglobulin (Ig) G4 monoclonal antibody (mAb) that works by neutralizing the IL-13 cytokine.(1) IL-13 plays a key role in driving the underlying chronic inflammation in AD.(2,6) By specifically binding to the IL-13 cytokine with high affinity, tralokinumab prevents its interaction with the receptor and the subsequent downstream IL-13 signalling.(1)

About the pivotal ECZTRA 1, 2 and ECZTRA 3 Phase 3 studies

ECZTRA 1 and ECZTRA 2 (ECZema TRAlokinumab trials Nos. 1 and 2) were randomized, double-blind, placebo-controlled, multinational, 52-week trials, which included 802 and 794 patients, respectively, to evaluate the safety and efficacy of tralokinumab (300 mg subcutaneous) as monotherapy in adults with moderate-to-severe AD who were candidates for systemic therapy.(3,4)

ECZTRA 3 (ECZema TRAlokinumab trial No. 3) was a double-blind, randomized, placebo-controlled, multinational 32-week study, which included 380 patients, to evaluate the safety and efficacy of tralokinumab (300 mg subcutaneous) in combination with topical corticosteroid (TCS) in adults with moderate-to-severe AD who were candidates for systemic therapy.(5)

About atopic dermatitis
Atopic dermatitis (AD) is a chronic, inflammatory, heterogeneous skin disease characterized by intense itch and eczematous lesions.(7) AD is the result of skin barrier dysfunction and immune dysregulation, leading to chronic inflammation.(8) Type-2 cytokines, including IL-13, play a central role in the key aspects of AD pathophysiology.(2,6)

1. Popovic B, et al. Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Rα1 and IL-13Rα2. J Mol Biol. 2017;429:208-219.

2. Bieber T. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75:54–62.

3. ClinicalTrials.gov. National Library of Medicine (U.S.). Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1) (ECZTRA 1). Identifier NCT03131648. https://clinicaltrials.gov/ct2/show/NCT03131648

4. ClinicalTrials.gov. National Library of Medicine (U.S.). Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2) (ECZTRA 2). Identifier CT03160885. https://www.clinicaltrials.gov/ct2/show/NCT03160885

5. ClinicalTrials.gov. National Library of Medicine (U.S.). Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3). Identifier NCT03363854. https://clinicaltrials.gov/ct2/show/study/NCT03363854

6. Tsoi LC, et al. Atopic dermatitis is an IL-13 dominant disease with greater molecular heterogeneity compared to psoriasis. J Invest Dermatol 2019;139:1480-1489.

7. Weidinger S, et al. Atopic dermatitis. Lancet 2016;387:1109-1122.

8. Boguniewicz M, et al. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev 2011;242(1):233-46.

MAT-35840 July 2020

Contacts

Linda Mayer
Global Product Communications
+1 973 908 7924
limay@leo-pharma.com

Henrik Kyndlev
Global External Communications
+45 3140 6180
hdtdk@leo-pharma.com

About LEO Pharma

LEO Pharma
LEO Pharma
Industriparken 55
2750 Ballerup

4494 5888http://www.leo-pharma.com/

The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries. For more information about LEO Pharma, visit www.leo-pharma.com.

Subscribe to releases from LEO Pharma

Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from LEO Pharma

LEO Pharma presents results from study of twice-weekly Enstilar® (calcipotriene and betamethasone dipropionate) Foam for topical use in long-term maintenance treatment of plaque psoriasis12.6.2020 21:20:42 CESTPress release

New results from the PSO-LONG clinical trial are the first to provide long-term maintenance data for plaque psoriasis with a twice-weekly topical treatment with Enstilar®(calcipotriene and betamethasone dipropionate) Foam Plaque psoriasis is a chronic, multifactorial disease affecting nearly 80% of the 125 million people living with psoriasis worldwide(1,2) LEO Pharma is committed to building on its more than 30-year heritage of pursuing innovative products for patients affected by psoriasis and other chronic skin conditions BALLERUP, Denmark, JUNE 12, 2020 – LEO Pharma A/S, a global leader in medical dermatology, today presented results from the Phase 3 PSO-LONG clinical trial. PSO-LONG compared the efficacy and safety of twice-weekly Enstilar® (calcipotriene and betamethasone dipropionate)Foam, versus foam vehicle for long-term (52-week) maintenance treatment for adult patients with plaque psoriasis.(3,4) Results were presented as ePosters online at the American Academy of Dermatolog

Tralokinumab achieves primary and secondary endpoints in three pivotal Phase 3 trials in adult patients with moderate-to-severe atopic dermatitis12.6.2020 21:06:15 CESTPress release

Presented at the AAD VMX 2020, results from ECZTRA 1, 2 and 3 trials confirm tralokinumab met its primary and secondary endpoints and are the first Phase 3 results in atopic dermatitis for an investigational therapy that specifically targets IL-13 Tralokinumab demonstrated statistically significant improvements in outcomes including pruritus (itch) and health-related quality of life measures that are important to patients In ECZTRA 1 and 2, the majority of patients treated with tralokinumab 300 mg every two weeks who achieved a clinical response at week 16, maintained response at week 52 without any use of topical corticosteroids In ECZTRA 3, nine out of 10 patients who achieved clear or almost clear skin with tralokinumab 300 mg in combination with topical corticosteroids at week 16 maintained this response at week 32 when randomized to dosing every two weeks. Similarly, eight out of 10 patients randomized to dosing every four weeks at week 16 maintained clear or almost clear skin at

LEO Pharma announces European Medicines Agency acceptance of marketing authorization application for tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis11.6.2020 14:00:00 CESTPress release

BALLERUP, Denmark, JUNE 11, 2020 – LEO Pharma A/S, a global leader in medical dermatology, today announced that the European Medicines Agency (EMA) validated the marketing authorization application (MAA) for tralokinumab, an investigational product for the treatment of adult patients with moderate-to-severe atopic dermatitis (AD). The acceptance of this MAA marks the beginning of the formal review procedure for this potential new treatment by the EMA’s Committee for Medicinal Products for Human Use (CHMP).

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom